According to Nova one advisor, the global 3D Printed Drugs market size is expected to hit around USD 319.74 million by 2030 from valued at USD 102.9 million in 2021 and growing at a CAGR of 16.32% from 2022 to 2030.
According to Nova one advisor, the global 3D Printed Drugs market size is expected to hit around USD 319.74 million by 2030 from valued at USD 102.9 million in 2021 and growing at a CAGR of 16.32% from 2022 to 2030.
Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7542
Key Takeaways:
- By technology, the zip dose segment held the largest share of the 3D market. This is attributed to the increase in the requirement for rapid soluble drugs that disperse quickly in the mouth, which in turn is likely to increase the adoption and anticipate market growth.
- The inkjet printer segment is expected to grow lucratively during the forecast period. Due to the 3D medications can be personalized to each patient’s needs, assisting them far more than batch-produced medicines, their demand is expected to skyrocket in the coming years.
- By application, the neurology segment held a larger share of the global market. This is attributed to an increase in the proportion of older people, which is at an increased risk of developing neurological disorders and hence, propelling the market growth.
- By end-use, the hospitals & clinics segment held a larger share in 2021, owing to the growing demand for personalized medicines and the cost-effective use of bio-drugs employing this technology.
- North America dominated the global market in 2021 due to the availability of technologically advanced healthcare research framework, the presence of high R&D investment, and the development of 3D printed drugs in the region.
- The Asia Pacific is expected to grow considerably in the future owing to the rising prevalence of chronic diseases and the presence of key players.
- A few of the key market players include 3D Printer Drug Machine, Aprecia Pharmaceuticals, BV LLC, Hewlett Packard Caribe, and others.
The rising prevalence of chronic diseases, combined with the rising population of patients with dysphagia around the globe is pushing the demand for immediate soluble medications, which is likely to drive the market. For instance, according to a study published in April 2022, the prevalence of oropharyngeal dysphagia is high in conditions such as stroke and aging and is reported to be 26.19% in the elderly.
An increase in the aging population has led to the growing demand for the development of easy-to-swallow pills for the elderly. The 3D printed highly soluble and easy-to-swallow drugs can help the elderly who have difficulty swallowing. Moreover, according to the United Nations, the number of people aged 65 and more in 2050 is projected to be 1.5 billion. Thus, the growing elderly population across the world would propel the demand for easy-to-swallow drugs resulting in market growth.
Other factors such as quickly expanding demand for pharmaceuticals, technical improvements in healthcare, as well as the government’s focus and expenditures in the 3D printing industry, are also contributing to the market’s growth. For instance, in March 2022, Evonik Venture Capital invested in Nevada-based Laxxon Medical for the manufacturing of 3D-printed tablets. The latter company has developed a 3D screen-printing technology for the production of structured tablets with the controlled release of API over time. Such investments are likely to supplement the market growth in the coming years.
The COVID-19 pandemic is anticipated to positively impact market growth. Several printers have been launched by the operating companies in the advanced manufacturing industry to help increase the manufacturing of medications and other necessary products. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic.
The growing demand for personalized medicine is expected to majorly drive market growth in the coming years. As 3D printing of pharmaceutical drugs can produce personalized medicine in small batches with carefully tailored shapes, dosages, and sizes, the market is anticipated to grow at an exponential rate in the near future. In addition, the use of 3D printing technology can significantly reduce manufacturing costs thus, further increasing investments in this space.
On the other hand, adverse effects from these drugs, the use of 3D printing to create illegal drugs, and a lack of government restrictions for 3D printed products are limiting the market’s growth. For instance, in March 2018, a police case was filed in Amsterdam, for the illegal handling of these drugs. However, increased awareness of the benefits of these medications, such as their immediate solubility, faster manufacturing time, reduced waste, and easy on-demand manufacturing is likely to create multiple prospects for market growth.
Report Scope of the 3D Printed Drugs Market
| Report Coverage | Details |
| Market Size | USD 319.74 million by 2030 |
| Growth Rate | CAGR of 16.32% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Technology, application, end-use, and Region, |
Technology Insights
The zip dose segment held the highest share of the market in 2021. This drug technology is easy to use and beneficial to patients with dysphagia. Furthermore, an increasing requirement among geriatric & pediatric patients for rapid soluble drugs that disperse quickly in the mouth drives the market growth.
Inkjet printer technology, on the other hand, is anticipated to expand at the fastest rate during the projected period. As it generates 3D drugs at a steady rate and has technological superiorities over other techniques, it has a high adoption rate among patients. Inkjet printing is a method of depositing three-dimensional shapes in solid dosage forms by spraying various combinations of active pharmaceutical ingredients and excipients (inks) through a nozzle. Furthermore, increased epilepsy incidences continued technological advancements in 3D printing technology, and expanding awareness of this technology in emerging nations are primary market growth drivers.
Application Insights
The neurology segment dominated the market with a share of 50.18% in 2021. In August 2015, the U.S. FDA approved Aprecia Pharmaceutical’s SPRITAM (levetiracetam) tablets for the treatment of people with epilepsy. This is the only approved drug available on the market. This approval has gained the attention of pharmaceutical companies to invest in this segment thereby propelling the market growth.
The segment is also propelled by an increase in the prevalence of various neurological disorders such as Parkinson’s disease. In an article published in April 2022, a team of scientists from Germany and the Netherlands used 3D printing technology for the manufacturing of Mini-Floating-Polypill as a therapy for Parkinson’s disease. Fused deposition modeling (FDM) was used for this study. Such research efforts are anticipated to supplement the segment growth.
On the other hand, orthopedic procedures are complex & tough, and new approaches are needed to overcome a slew of known issues and better patient outcomes. In addition, complications, particularly the high rate of infection, frequently result in extended patient suffering and functional loss. Thus, orthopedic drugs can be used to combat postoperative infections, hence, propelling the market growth.
End-use Insights
The hospitals & clinics segment captured the highest revenue share of the market in 2021. The widespread use of prescription pills to treat a variety of chronic diseases is moving the market for personalized pharmaceuticals forward. The segment is also being driven by the growing demand for pharmaceuticals and the cost-effective use of bio-drugs employing this technology.
Furthermore, in hospitals and clinics, these printers can be installed to enable the on-demand manufacturing of medications, specifically those with poor stability or that need to be stored in a cold chain. Additionally, it can considerably save expenses, waste, and environmental strain. These factors are anticipated to increase the adoption of 3D-printed drugs among hospitals and clinics.
Regional Insights
North America dominated the regional market with a share of 38.23% in 2021. This major share can be attributed to an increased incidence of chronic diseases, the presence of excellent domestic healthcare infrastructure, strong investment in R&D, and the expanding use of technological developments in the North America region.
The Asia Pacific is estimated to be the fastest-growing region due to significant developments by China and Japan in the technological integration of 3D printed drug methodologies. Moreover, the development of healthcare infrastructure, R&D, and clinical development frameworks of emerging economies such as India and Australia have poised the Asia Pacific market to witness lucrative opportunities and growth throughout the forecast period.
Some of the prominent players in the 3D Printed Drugs Market include:
- Aprecia
- Extend Biosciences
- Bioduro
- Affinity Therapeutics
- Osmotica Pharmaceuticals
- Aprecia Pharmaceuticals LLC
- GlaxoSmithKline Plc
- FabRx Ltd
- Hewlett Packard Caribe
- Merck
- Cycle Pharmaceuticals
- AstraZeneca
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global 3D Printed Drugs market
- Technology
- Inkjet Printing
- Fused Deposition Modeling
- Stereolithography
- ZipDose Technology
- Application
- Orthopedic
- Neurology
- Dental
- Others
- End-use
- Hospitals & clinics
- Research Laboratories
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7542
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/